Methods	Ten-week randomised, double-blind, multicentre study.
Participants	Patients fulfilling DSM-IV criteria for major depressive episode, lasting for at least 1 month and having Columbia criteria for atypical depression. Age range: 18-65 years old. Exclusion criteria: significant suicidal risk, pregnancy, lactation, absence of contraception, unstable and serious physical illness, history of seizures, psychosis or organic mental syndrome, substance use disorder within 6 months, history of mania, antisocial personality disorder, history of non-response to an adequate trial of fluoxetine or imipramine, history of no response to any other SSRIs, hypothyroidism
Interventions	Fluoxetine: 49 participants. Imipramine: 53 participants. Placebo: 52 participants. Fluoxetine dose range: 20-60 mg/day. Imipramine dose range: 50-300 mg/day.
Outcomes	Hamilton Rating Scale for Depression, CGI.
Notes	Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear